Read by QxMD icon Read

Gastric cancer AND radiotherapy

D Rades, T Bartscht, S E Schild
This study aims to identify predictors of survival and contribute to treatment personalization in patients with brain metastases from gastric cancer. Twelve patients received whole-brain radiotherapy (WBRT), four stereotactic radiosurgery and six neurosurgery plus WBRT. Treatment regimen, age, gender, Eastern Cooperative Oncology Group (ECOG) performance score, tumor site, number of brain metastases, extra-cranial metastases and interval between cancer diagnosis and brain metastases were evaluated for survival...
November 24, 2016: Neoplasma
Lisanne Sara Rigter, Frank G J Kallenberg, Barbara Bastiaansen, Theo A M van Os, Floor E van Leeuwen, Monique Esther van Leerdam, Evelien Dekker
BACKGROUND: In a large number of patients with multiple gastrointestinal adenomatous polyps, no causal germline mutation can be found. Non-genetic factors may contribute to the development of adenomatous polyps in these unexplained polyposis patients. In the development of gastrointestinal cancer, prior exposure to abdominal radiotherapy has been identified as such a factor, as it increases the gastrointestinal cancer risk in cancer survivors. A relationship of radiotherapy with intestinal polyposis, however, has not yet been described...
November 8, 2016: BMC Cancer
S Berretta, M Berretta, F Fiorica, R Di Francia, P Magistri, G Bertola, R Fisichella, V Canzonieri, F Di Benedetto, G Tarantino
Gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide, with the highest estimated mortality rates in Eastern Asia and the lowest in Northern America. However, the availability of modern treatment has improved the survival and the prognosis is often poor due to biological characteristics of the disease. In oncology, we are living in the "Era" of target treatment and, to know biological aspects, prognostic factors and predictive response informations to therapy in GC is mandatory to apply the best strategy of treatment...
October 2016: European Review for Medical and Pharmacological Sciences
L-C Horn, C E Brambs, R Handzel, S Lax, I Sändig, D Schmidt, K Schierle
The World Health Organization (WHO) classification from 2014 differentiates between different subtypes of mucinous adenocarcinoma of the uterine cervix. A gastric subtype was recently described that showed no association with high-risk human papillomavirus (HPV) infections, has a poor prognosis, is mainly diagnosed in women of Asian origin and can occur in patients with Peutz-Jeghers syndrome. Although no clear grading system has been recommended in the WHO classification, it is likely that grading of adenocarcinomas of the uterine cervix will partly be based on the different patterns of invasion...
October 20, 2016: Der Pathologe
Jianjun Liu, Mingxue Su, Jing Wang, Gan Zhang, Jing Zhou, Anqing Zhang, Zixue Ren, Xucai Zheng, Shikai Hong, Shengying Wang, Rongxin Zhang
Although local advanced gastric cancer (AGC) could benefit from neoadjuvant radiotherapy (NRT), there are few studies evaluating patients' survival after NRT. In current study, we aimed to investigate the value of prognostic factors in AGC patients after NRT and to evaluate whether post-therapy pathological characteristics were predictive factors in these patients. We retrospectively analyzed AGC patients who underwent NRT from Surveillance, Epidemiology, and End Results (SEER) Database. The patients' clinical and post-therapy pathological characteristics were analyzed...
October 11, 2016: Oncotarget
Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira, Shumei Song, Hideo Baba, Jaffer A Ajani
The prognosis for patients with upper gastrointestinal cancers remains dismal despite the development of multimodality therapies that incorporate surgery, chemotherapy, and radiotherapy. Early diagnosis and personalized treatment should lead to better prognosis. Given the advances in proteomic technologies over the past decades, proteomics promises to be the most effective technique to identify novel diagnostics and therapeutic targets. Areas covered: For this review, keywords were searched in combination with "proteomics" and "gastric cancer" or "esophageal cancer" in PubMed...
October 10, 2016: Expert Review of Proteomics
Peng Gao, Chengche Tsai, Yuchong Yang, Yingying Xu, Changwang Zhang, Cong Zhang, Longyi Wang, Hongpeng Liu, Zhenning Wang
BACKGROUND: The treatment effects of intraoperative radiotherapy (IORT) for gastric and esophageal cancer remain uncertain. We therefore performed meta-analyses to investigate whether IORT was associated with more favorable oncologic outcomes when compared to non-IORT for patients who have gastric or esophageal cancer. METHODS: PubMed, Embase, and the references of relevant studies were systematically searched up to March 2016. Outcomes were analyzed with fixed-effect or random-effect models, and the meta-analysis was completed with odds ratio (OR), hazards ratio (HR), and 95% confidence intervals (CI) as effect values...
October 4, 2016: Minerva Medica
Hideaki Kawabata, Koji Uno, Kenjiro Yasuda, Masato Yamashita
BACKGROUND/AIMS: The optimal regimen of radiotherapy (RT) for bleeding from gastric cancer (GC) has not yet been established. The aim of this study was to evaluate the usefulness of low-dose, short-course palliative RT (LSP-RT) for bleeding from GC. MATERIAL AND METHODS: We reviewed the clinical data of 18 patients (26 courses) who received palliative RT for bleeding from GC between 2004 and 2014. The radiation dose was 6 Gy in three fractions. The total courses of RT for each patient were 1-4 (median, 1)...
September 27, 2016: Journal of Palliative Medicine
T Taki, Y Hoya, A Watanabe, T Nakayoshi, T Okamoto, H Sekine, N Mitsumori, K Yanaga
Introduction Radiotherapy is not commonly used for the treatment of gastric cancer in Japan, where surgery is the standard local treatment. We report the results of chemoradiotherapy in patients with advanced or recurrent gastric cancer which was deemed difficult to treat surgically. Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed...
September 23, 2016: Annals of the Royal College of Surgeons of England
Phu Hung Nguyen, Julie Giraud, Lucie Chambonnier, Pierre Dubus, Linda Wittkop, Genevieve Belleannée, Denis Collet, Isabelle Soubeyran, Serge Evrard, Benoit Rousseau, Nathalie Dugot-Senant, Francis Mégraud, Frédéric Mazurier, Christine Varon
PURPOSE: Gastric carcinomas (GC) are heterogeneous, and the current therapy remains essentially based on surgery with conventional chemo- and radiotherapy. This study aimed to characterize biomarkers allowing the detection of cancer stem cells (CSC) in human GC of different histological types. EXPERIMENTAL DESIGN: The primary tumors from thirty-seven patients with intestinal or diffuse type non-cardia GC were studied, and patient's derived tumor xenograft (PDX) models in immunodeficient mice were developed...
September 12, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
J-M Cosset
Radiotherapy is 120 years old. A few months only after the discoveries of Roentgen, Becquerel and Marie and Pierre Curie, a few scientists tried to use the newly discovered rays to treat patients. The question of the name of the first "radiation therapist" remains debated. Although often proposed, Emil Grubbé from Chicago seems to have been disqualified. Leopold Freund from Vienna treated a benign cutaneous lesion. Finally, Victor Despeignes from Lyon appears to be the most serious candidate, having treated in 1896 a gastric cancer, and obtaining a very significant tumour regression...
October 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Wojciech Leszczyński, Paweł Polanowski, Paulina Leszczyńska, Leszek Hawrylewicz, Iwona Brąclik, Rafał Kawczyński, Jerzy Wydmański
AIM: The purpose of this study was to compare conformal radiotherapy techniques used in the treatment of gastric cancer patients. The study is dedicated to radiotherapy centres that have not introduced dynamic techniques in clinical practice. BACKGROUND: The implementation of multi-field technique can minimise the toxicity of treatment and improve dose distribution homogeneity in the target volume with simultaneous protection of organs at risk (OaRs). Treatment plan should be personalised for each patient by taking into account the planning target volume and anatomical conditions of the individual patient...
May 2016: Reports of Practical Oncology and Radiotherapy
Vivek Verma, Steven H Lin, Charles B Simone, Minesh P Mehta
BACKGROUND: Proton beam radiotherapy (PBT) is frequently shown to be dosimetrically superior to photon radiotherapy (RT), though supporting data for clinical benefit are severely limited. Because of the potential for toxicity reduction in gastrointestinal (GI) malignancies, we systematically reviewed the literature on clinical outcomes (survival/toxicity) of PBT. METHODS: A systematic search of PubMed, EMBASE, abstracts from meetings of the American Society for Radiation Oncology, Particle Therapy Co-Operative Group, and American Society of Clinical Oncology was conducted for publications from 2000-2015...
August 2016: Journal of Gastrointestinal Oncology
Mozaffar Aznab, Omid Beiki, Kiumars Eslam Pia, Khosro Setayeshi, Mohamad Ali Hesami, Houshang Vrae
AIM: Our aim was to evaluate impact of chemotherapy (5-fluorouracil plus docetaxel and cisplatin) on the survival of gastric cancer cases. METHOD: Seventy-nine patients were eligible to take part in this study between November 2006 and April 2013, who received 5-fluorouracil (700 mg/m(2), 21-h infusion within 5 days), cisplatin (60 mg/m(2) on day 3), and Docetaxel (60 mg/m(2) on day 2). Radiotherapy was added to the treatment only in the cases with entire stomach body cancer (positive margin) and with giant ulcer (above 50 mm) in proximal gastric cancer...
August 20, 2016: Journal of Gastrointestinal Cancer
Patricia Martin-Romano, Jose J Sola, Juan A Diaz-Gonzalez, Ana Chopitea, Yohana Iragorri, Fernando Martínez-Regueira, Mariano Ponz-Sarvise, Leire Arbea, Jose C Subtil, David Cano, Lucia Ceniceros, Jairo Legaspi, Jose Luis Hernandez, Javier Rodríguez
BACKGROUND: The degree of histopathological response after neoadjuvant therapy in locally advanced gastric cancer (GC) is a key determinant of patients' long-term outcome. We aimed to assess the pattern of histopathological regression after two neoadjuvant approaches and its impact on survival times. METHODS: Regression grade of the primary tumour (Becker criteria) and the degree of nodal response by a 4-point scale (grades A-D) were assessed. Grade A-true negative lymph nodes (LNs); grade B and C-infiltrated LNs with any or little evidence of nodal response; and grade D-complete pathological response in a previously infiltrated LN...
September 6, 2016: British Journal of Cancer
A L Mahar, N G Coburn, D J Kagedan, R Viola, A P Johnson
BACKGROUND: Geographic variation in cancer care is common when clear clinical management guidelines do not exist. In the present study, we sought to describe health care resource consumption by patients with metastatic gastric cancer (gc) and to investigate the possibility of regional variation. METHODS: In this population-based cohort study of patients with stage iv gastric adenocarcinoma diagnosed between 1 April 2005 and 31 March 2008, chart review and administrative health care data were linked to study resource utilization outcomes (for example, clinical investigations, treatments) in the province of Ontario...
August 2016: Current Oncology
G Créhange, F Huguet, L Quero, T V N'Guyen, X Mirabel, T Lacornerie
Localized oesophageal and gastric cancers have a poor prognosis. In oesophageal cancer, external radiotherapy combined with concomitant chemotherapy is accepted as part of the therapeutic armamentarium in a curative intent in the preoperative setting for resectable tumours; or without surgery in inoperable patients or non-resectable tumours due to wide local and/or regional extension. Data from the literature show conflicting results with no clinical evidence in favour of either a unique dose protocol or consensual target volume definition in the setting of exclusive chemoradiation...
September 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Min Dong, Jingwang Bi, Xiaohong Liu, Baocheng Wang, Jun Wang
INTRODUCTION: Myxoid/round cell liposarcoma is the second most common subtype of liposarcoma. Chemotherapy and radiotherapy have a limited efficacy for treating advanced myxoid/round cell liposarcoma, with relatively serious side effects. CASE PRESENTATION: We herein present a 68-year-old Chinese woman initially diagnosed with advanced multiple intra-abdominal and pelvic round cell liposarcoma.She refused to receive cytotoxic chemotherapy and received apatinib as the first-line therapy, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 that has been used in the treatment of patients with metastatic gastric cancer who progressed with 2 or more chemotherapy regimens...
August 2016: Medicine (Baltimore)
Kate Young, Naureen Starling, David Cunningham
INTRODUCTION: Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has been identified as a tumour where a subgroup of patients demonstrates deficiencies in the homologous recombination pathway providing a potential novel treatment approach for this poor prognosis disease. AREA COVERED: This review provides an overview of DNA damage repair and how this has been targeted to date in other tumour types exploiting the concept of synthetic lethality...
September 2016: Expert Opinion on Pharmacotherapy
Marwa Matboli, Sarah El-Nakeep, Nourhan Hossam, Alaa Habieb, Ahmed E M Azazy, Ali E Ebrahim, Ziad Nagy, Omar Abdel-Rahman
Gastric cancer (GC) is a global health problem and a major cause of cancer-related death with high recurrence rates ranging from 25% to 40% for GC patients staging II-IV. Unfortunately, while the majority of GC patients usually present with advanced tumor stage; there is still limited evidence-based therapeutic options. Current approach to GC management consists mainly of; endoscopy followed by, gastrectomy and chemotherapy or chemo-radiotherapy. Recent studies in GC have confirmed that it is a heterogeneous disease...
July 14, 2016: World Journal of Gastroenterology: WJG
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"